{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:26:29Z","timestamp":1789424789322,"version":"build-2803163510"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40273-021-01095-6","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T22:17:10Z","timestamp":1634509030000},"page":"69-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)"],"prefix":"10.1007","volume":"40","author":[{"given":"Noman","family":"Paracha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pollyanna","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-1374","authenticated-orcid":false,"given":"C. Simone","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"2","key":"1095_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","volume":"3","author":"TO Crawford","year":"1996","unstructured":"Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis. 1996;3(2):97\u2013110. https:\/\/doi.org\/10.1006\/nbdi.1996.0010.","journal-title":"Neurobiol Dis"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet. 2020;21:231\u201361. https:\/\/doi.org\/10.1146\/annurev-genom-102319-103602.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"3","key":"1095_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","volume":"15","author":"B Wirth","year":"2000","unstructured":"Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228\u201337. https:\/\/doi.org\/10.1002\/(SICI)1098-1004(200003)15:3%3c228::AID-HUMU3%3e3.0.CO;2-9.","journal-title":"Hum Mutat"},{"issue":"4","key":"1095_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004.","journal-title":"Neurol Clin"},{"issue":"11","key":"1095_CR5","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999;96(11):6307\u201311. https:\/\/doi.org\/10.1073\/pnas.96.11.6307.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1095_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033572","volume":"7","author":"TO Crawford","year":"2012","unstructured":"Crawford TO, Paushkin SV, Kobayashi DT, Forrest SJ, Joyce CL, Finkel RS, et al. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS ONE. 2012;7(4): e33572. https:\/\/doi.org\/10.1371\/journal.pone.0033572.","journal-title":"PLoS ONE"},{"issue":"2","key":"1095_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldkotter","year":"2002","unstructured":"Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70(2):358\u201368. https:\/\/doi.org\/10.1086\/338627.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1095_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/acn3.689","volume":"6","author":"A Saffari","year":"2019","unstructured":"Saffari A, Kolker S, Hoffmann GF, Weiler M, Ziegler A. Novel challenges in spinal muscular atrophy\u2014how to screen and whom to treat? Ann Clin Transl Neurol. 2019;6(1):197\u2013205. https:\/\/doi.org\/10.1002\/acn3.689.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"1095_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/ejpn.1999.0181","volume":"3","author":"V Dubowitz","year":"1999","unstructured":"Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol. 1999;3(2):49\u201351. https:\/\/doi.org\/10.1053\/ejpn.1999.0181.","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"1095_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0960-8966(91)90052-T","volume":"1","author":"TL Munsat","year":"1991","unstructured":"Munsat TL. International SMA Collaboration. Neuromuscul Disord. 1991;1(2):81. https:\/\/doi.org\/10.1016\/0960-8966(91)90052-T.","journal-title":"Neuromuscul Disord"},{"issue":"5\u20136","key":"1095_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/s0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat TL, Davies KE. International SMA Consortium meeting (26\u201328 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2(5\u20136):423\u20138. https:\/\/doi.org\/10.1016\/s0960-8966(06)80015-5.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"1095_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/gt.2017.52","volume":"24","author":"K Talbot","year":"2017","unstructured":"Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24(9):529\u201333. https:\/\/doi.org\/10.1038\/gt.2017.52.","journal-title":"Gene Ther"},{"key":"1095_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/gt.2017.52","volume":"15","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey. Orphanet J Rare Dis. 2020;15:217.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1095_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(12)70061-3.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1095_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1095_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-020-1339-3","volume":"15","author":"HWY Wan","year":"2020","unstructured":"Wan HWY, Carey KA, D\u2019Silva A, Vucic S, Kiernan MC, Kasparian NA, et al. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet J Rare Dis. 2020;15(1):70. https:\/\/doi.org\/10.1186\/s13023-020-1339-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1095_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518\u201323. https:\/\/doi.org\/10.1001\/archneur.1995.00540290108025.","journal-title":"Arch Neurol"},{"issue":"5\u20136","key":"1095_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0960-8966(94)90090-6","volume":"4","author":"NH Thomas","year":"1994","unstructured":"Thomas NH, Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord. 1994;4(5\u20136):497\u2013502. https:\/\/doi.org\/10.1016\/0960-8966(94)90090-6.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"1095_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000000741.","journal-title":"Neurology"},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"1095_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027\u201349. https:\/\/doi.org\/10.1177\/0883073807305788.","journal-title":"J Child Neurol"},{"issue":"1","key":"1095_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy\u2014new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313. https:\/\/doi.org\/10.3233\/JND-190424.","journal-title":"J Neuromuscul Dis."},{"issue":"3","key":"1095_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004.","journal-title":"Neuromuscul Disord"},{"key":"1095_CR24","volume-title":"SPINRAZA\u00ae (nusinersen) [package insert]","author":"Food and Drug Administration","year":"2016","unstructured":"Food and Drug Administration. SPINRAZA\u00ae (nusinersen) [package insert]. Cambridge: Biogen Inc.; 2016."},{"key":"1095_CR25","unstructured":"European Medicines Agency. Spinraza. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza. Accessed 06 Nov 2020."},{"key":"1095_CR26","volume-title":"ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) [package insert]","author":"Food and Drug Administration","year":"2019","unstructured":"Food and Drug Administration. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) [package insert]. Bannockburn: AveXis Inc.; 2019."},{"key":"1095_CR27","unstructured":"European Medicines Agency. Zolgensma. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma. Accessed 06 Nov 2020."},{"key":"1095_CR28","volume-title":"EVRYSDI\u2122 (risdiplam) [package insert]","author":"Food and Drug Administration","year":"2020","unstructured":"Food and Drug Administration. EVRYSDI\u2122 (risdiplam) [package insert]. South San Francisco: Genentech Inc.; 2020."},{"key":"1095_CR29","unstructured":"European Medicines Agency. Risdiplam. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi. Accessed 05 May 2021."},{"issue":"1","key":"1095_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1083\/jcb.201207087","volume":"199","author":"F Rigo","year":"2012","unstructured":"Rigo F, Hua Y, Krainer AR, Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol. 2012;199(1):21\u20135. https:\/\/doi.org\/10.1083\/jcb.201207087.","journal-title":"J Cell Biol"},{"issue":"18","key":"1095_CR31","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"issue":"15","key":"1095_CR32","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00741.","journal-title":"J Med Chem"},{"issue":"10063","key":"1095_CR33","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(16)31408-8.","journal-title":"Lancet"},{"issue":"3","key":"1095_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JND-190403","volume":"6","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Kolb SJ, Lowes L, Alfano LN, Shell R, Church KR, et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis. 2019;6(3):307\u201317. https:\/\/doi.org\/10.3233\/JND-190403.","journal-title":"J Neuromuscul Dis."},{"issue":"11","key":"1095_CR35","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007.","journal-title":"Neuromuscul Disord"},{"issue":"21","key":"1095_CR36","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92(21):e2492\u2013506. https:\/\/doi.org\/10.1212\/WNL.0000000000007527.","journal-title":"Neurology"},{"key":"1095_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","volume":"98","author":"LP Lowes","year":"2019","unstructured":"Lowes LP, Alfano LN, Arnold WD, Shell R, Prior TW, McColly M, et al. Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39\u201345. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.05.005.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"1095_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.26633","volume":"60","author":"J Montes","year":"2019","unstructured":"Montes J, Dunaway Young S, Mazzone ES, Pasternak A, Glanzman AM, Finkel RS, et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve. 2019;60(4):409\u201314. https:\/\/doi.org\/10.1002\/mus.26633.","journal-title":"Muscle Nerve"},{"issue":"10","key":"1095_CR39","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2009965.","journal-title":"N Engl J Med"},{"issue":"5","key":"1095_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142di\u0144ska M, Rose K, Xiong H, Zanoteli E. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2102047.","journal-title":"N Engl J Med"},{"issue":"4","key":"1095_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","volume":"44","author":"B Wirth","year":"2021","unstructured":"Wirth B. Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci. 2021;44(4):306\u201322. https:\/\/doi.org\/10.1016\/j.tins.2020.11.009.","journal-title":"Trends Neurosci"},{"issue":"11","key":"1095_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41582-020-00410-7","volume":"16","author":"MA Farrar","year":"2020","unstructured":"Farrar MA, Kiernan MC. Spinal muscular atrophy\u2014the dawning of a new era. Nat Rev Neurol. 2020;16(11):593\u20134. https:\/\/doi.org\/10.1038\/s41582-020-00410-7.","journal-title":"Nat Rev Neurol"},{"issue":"18","key":"1095_CR43","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMe1712106","volume":"377","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT. The dilemma of two innovative therapies for spinal muscular atrophy. N Engl J Med. 2017;377(18):1786\u20137. https:\/\/doi.org\/10.1056\/NEJMe1712106.","journal-title":"N Engl J Med"},{"issue":"10","key":"1095_CR44","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.18553\/jmcp.2017.23.10.1078","volume":"23","author":"TJ Mattingly 2nd","year":"2017","unstructured":"Mattingly TJ 2nd, Simoni-Wastila L. Patient-centered drug approval: the role of patient advocacy in the drug approval process. J Manag Care Spec Pharm. 2017;23(10):1078\u201382. https:\/\/doi.org\/10.18553\/jmcp.2017.23.10.1078.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1095_CR45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1017\/S0266462314000464","volume":"30","author":"K Facey","year":"2014","unstructured":"Facey K, Granados A, Guyatt G, Kent A, Shah N, van der Wilt GJ, et al. Generating health technology assessment evidence for rare diseases. Int J Technol Assess Health Care. 2014;30(4):416\u201322. https:\/\/doi.org\/10.1017\/S0266462314000464.","journal-title":"Int J Technol Assess Health Care"},{"key":"1095_CR46","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.publhealth.21.1.587","volume":"21","author":"PJ Neumann","year":"2000","unstructured":"Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000;21:587\u2013611. https:\/\/doi.org\/10.1146\/annurev.publhealth.21.1.587.","journal-title":"Annu Rev Public Health"},{"issue":"5","key":"1095_CR47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jval.2018.03.004","volume":"21","author":"S Nestler-Parr","year":"2018","unstructured":"Nestler-Parr S, Korchagina D, Toumi M, Pashos CL, Blanchette C, Molsen E, et al. Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2018;21(5):493\u2013500. https:\/\/doi.org\/10.1016\/j.jval.2018.03.004.","journal-title":"Value Health."},{"issue":"12","key":"1095_CR48","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.18553\/jmcp.2019.25.12.1300","volume":"25","author":"SD Pearson","year":"2019","unstructured":"Pearson SD, Thokala P, Stevenson M, Rind D. The effectiveness and value of treatments for spinal muscular atrophy. J Manag Care Spec Pharm. 2019;25(12):1300\u20136. https:\/\/doi.org\/10.18553\/jmcp.2019.25.12.1300.","journal-title":"J Manag Care Spec Pharm"},{"key":"1095_CR49","unstructured":"ICER. Assessing the effectiveness and value of drugs for rare conditions. 2017. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Assessing-the-Value-of-Drugs-for-Rare-Conditions_051017-1.pdf. Accessed 6 Nov 2019."},{"key":"1095_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"3","key":"1095_CR51","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","volume":"123","author":"WS Richardson","year":"1995","unstructured":"Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12\u20133.","journal-title":"ACP J Club"},{"issue":"7052","key":"1095_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275\u201383. https:\/\/doi.org\/10.1136\/bmj.313.7052.275.","journal-title":"BMJ"},{"key":"1095_CR53","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.jval.2019.04.060","volume":"22","author":"D Malone","year":"2019","unstructured":"Malone D, Dean R, Miller B, Arjunji R, Feltner DE, Sproule DM, et al. ND2 cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy Type 1 compared to chronic nusinersen treatment. Value Health. 2019;22:S42\u20133. https:\/\/doi.org\/10.1016\/j.jval.2019.04.060.","journal-title":"Value Health."},{"key":"1095_CR54","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.jval.2019.04.1648","volume":"22","author":"P Thokala","year":"2019","unstructured":"Thokala P, Stevenson M, Kumar VM, Ren S, Chapman R, Ellis A, et al. PRO15 cost-effectiveness of nusinersen and onasemnogene abeparvovec for infantile-onset spinal muscular atrophy (Type I SMA) in the US. Value Health. 2019;22:S337\u20138. https:\/\/doi.org\/10.1016\/j.jval.2019.04.1648.","journal-title":"Value Health."},{"key":"1095_CR55","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.jval.2019.04.1647","volume":"22","author":"S Zuluaga-Sanchez","year":"2019","unstructured":"Zuluaga-Sanchez S, Purser M, Mader G, Gould IG, Knight C, Johnson NB, et al. PRO14 improved quality of life and life-years in patients with infantile-onset SMA following treatment with nusinersen. Value Health. 2019;22:S337. https:\/\/doi.org\/10.1016\/j.jval.2019.04.1647.","journal-title":"Value Health."},{"key":"1095_CR56","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1016\/j.jval.2019.04.1649","volume":"22","author":"S Zuluaga-Sanchez","year":"2019","unstructured":"Zuluaga-Sanchez S, Purser M, Mader G, Gould IG, Knight C, Patel M, et al. PRO16 improved quality of life for patients and caregivers among patients with later-onset sma following treatment with nusinersen. Value Health. 2019;22:S338. https:\/\/doi.org\/10.1016\/j.jval.2019.04.1649.","journal-title":"Value Health."},{"issue":"1","key":"1095_CR57","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7(1):1601484. https:\/\/doi.org\/10.1080\/20016689.2019.1601484.","journal-title":"J Mark Access Health Policy."},{"issue":"6","key":"1095_CR58","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","volume":"37","author":"S Zuluaga-Sanchez","year":"2019","unstructured":"Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, et al. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019;37(6):845\u201365. https:\/\/doi.org\/10.1007\/s40273-019-00769-6.","journal-title":"Pharmacoeconomics"},{"key":"1095_CR59","unstructured":"CADTH. Pharmacoeconomic review report nusinersen (Spinraza). 2018. https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0525_Spinraza_PE_Report.pdf. Accessed 06 Nov 2019."},{"key":"1095_CR60","unstructured":"NICE. TA588 Nusinersen for treating spinal muscular atrophy. 2018. https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/committee-papers. Accessed 06 Nov 2019."},{"key":"1095_CR61","unstructured":"ICER. Spinraza\u00ae and Zolgensma\u00ae for spinal muscular atrophy: effectiveness and value. 2019. https:\/\/icer-review.org\/wp-content\/uploads\/2018\/07\/ICER_SMA_Final_Evidence_Report_040319.pdf. Accessed 06 Nov 2019."},{"issue":"18","key":"1095_CR62","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"N Engl J Med"},{"issue":"7","key":"1095_CR63","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1710504.","journal-title":"N Engl J Med"},{"issue":"2 Pt 1","key":"1095_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/s0022-3476(99)70016-8","volume":"135","author":"L Haataja","year":"1999","unstructured":"Haataja L, Mercuri E, Regev R, Cowan F, Rutherford M, Dubowitz V, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr. 1999;135(2 Pt 1):153\u201361. https:\/\/doi.org\/10.1016\/s0022-3476(99)70016-8.","journal-title":"J Pediatr"},{"key":"1095_CR65","doi-asserted-by":"publisher","unstructured":"Group WHOMGRS. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl. 2006;450:86\u201395. https:\/\/doi.org\/10.1111\/j.1651-2227.2006.tb02379.x.","DOI":"10.1111\/j.1651-2227.2006.tb02379.x"},{"issue":"3","key":"1095_CR66","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155\u201361. https:\/\/doi.org\/10.1016\/j.nmd.2009.11.014.","journal-title":"Neuromuscul Disord"},{"issue":"9\u201310","key":"1095_CR67","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O'Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9\u201310):693\u20137. https:\/\/doi.org\/10.1016\/j.nmd.2007.05.009.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"1095_CR68","doi-asserted-by":"publisher","first-page":"A725","DOI":"10.1016\/j.jval.2017.08.1962","volume":"20","author":"R Thompson","year":"2017","unstructured":"Thompson R, Vaidya S, Teynor M. The utility of different approachs to developing health utilities data in childhood rare diseases\u2014a case study in spinal muscular atrophy (SMA). Value Health. 2017;20(9):A725\u20136. https:\/\/doi.org\/10.1016\/j.jval.2017.08.1962.","journal-title":"Value Health."},{"issue":"4","key":"1095_CR69","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006;26(4):410\u201320. https:\/\/doi.org\/10.1177\/0272989X06290495.","journal-title":"Med Decis Mak"},{"key":"1095_CR70","unstructured":"Tappenden P, Hamilton J, Kaltenthaler E, Hock E, Rawdin A, Mukuria C, et al. Nusinersen for treating spinal muscular atrophy: a single technology appraisal. In: School of health and related research (ScHARR). 2018. https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/appraisal-consultation-document. Accessed 6 Nov 2019."},{"key":"1095_CR71","unstructured":"Bastida JL and Research Team. Social economic costs and health-related quality of life in patients with spinal muscular atrophy in Europe. University of Castilla-La Mancha (Ciudad Real, Spain); Toledo, Spain; 2016."},{"issue":"7","key":"1095_CR72","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1023\/a:1013171831202","volume":"10","author":"K Burstrom","year":"2001","unstructured":"Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621\u201335. https:\/\/doi.org\/10.1023\/a:1013171831202.","journal-title":"Qual Life Res"},{"key":"1095_CR73","doi-asserted-by":"publisher","unstructured":"Lucas F. Improving market access to rare disease therapies: a worldwide perspective with recommendations to the industry. Medicine Access @ Point of Care. 2018;2:2399202618810121. https:\/\/doi.org\/10.1177\/2399202618810121","DOI":"10.1177\/2399202618810121"},{"issue":"9","key":"1095_CR74","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40273-021-01050-5","volume":"39","author":"KM Facey","year":"2021","unstructured":"Facey KM, Espin J, Kent E, Link A, Nicod E, O\u2019Leary A, et al. Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel. Pharmacoeconomics. 2021;39(9):1021\u201344. https:\/\/doi.org\/10.1007\/s40273-021-01050-5.","journal-title":"Pharmacoeconomics"},{"key":"1095_CR75","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","volume":"18","author":"P Thokala","year":"2020","unstructured":"Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18:41. https:\/\/doi.org\/10.1186\/s12962-020-00234-8.","journal-title":"Cost Eff Resour Alloc."},{"issue":"1","key":"1095_CR76","doi-asserted-by":"publisher","first-page":"1889841","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma(R)) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9(1):1889841. https:\/\/doi.org\/10.1080\/20016689.2021.1889841.","journal-title":"J Mark Access Health Policy."},{"issue":"1","key":"1095_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47. https:\/\/doi.org\/10.1186\/s13023-021-01695-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"1095_CR78","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14712598.2020.1772747","volume":"20","author":"M Connock","year":"2020","unstructured":"Connock M, Andronis L, Auguste P, Dussart C, Armoiry X. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent \u201cvalue for money\u201d for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert Opin Biol Ther. 2020;20(7):823\u20137. https:\/\/doi.org\/10.1080\/14712598.2020.1772747.","journal-title":"Expert Opin Biol Ther"},{"key":"1095_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-020-00624-2","author":"E Landfeldt","year":"2021","unstructured":"Landfeldt E, Pechmann A, McMillan HJ, Lochmuller H, Sejersen T. Costs of illness of spinal muscular atrophy: a systematic review. Appl Health Econ Health Policy. 2021. https:\/\/doi.org\/10.1007\/s40258-020-00624-2.","journal-title":"Appl Health Econ Health Policy"},{"issue":"274\u201380","key":"1095_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.07.033","volume":"227","author":"A Jalali","year":"2020","unstructured":"Jalali A, Rothwell E, Botkin JR, Anderson RA, Butterfield RJ, Nelson RE. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy. J Pediatr. 2020;227(274\u201380): e2. https:\/\/doi.org\/10.1016\/j.jpeds.2020.07.033.","journal-title":"J Pediatr"},{"issue":"1","key":"1095_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/2249-4863.109934","volume":"2","author":"S Gopalakrishnan","year":"2013","unstructured":"Gopalakrishnan S, Ganeshkumar P. Systematic reviews and meta-analysis: understanding the best evidence in primary healthcare. J Family Med Prim Care. 2013;2(1):9\u201314. https:\/\/doi.org\/10.4103\/2249-4863.109934.","journal-title":"J Family Med Prim Care."},{"issue":"10","key":"1095_CR82","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27(10):883\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2017.05.011.","journal-title":"Neuromuscul Disord"},{"key":"1095_CR83","doi-asserted-by":"publisher","first-page":"S345","DOI":"10.1016\/j.jval.2020.04.1313","volume":"23","author":"SH Lo","year":"2020","unstructured":"Lo SH, Paracha N, Ali S, Lloyd A. PRO92 estimating disutilities in spinal muscular atrophy using a stated preference survey: a UK general public study. Value Health. 2020;23:S345. https:\/\/doi.org\/10.1016\/j.jval.2020.04.1313.","journal-title":"Value Health."},{"issue":"1","key":"1095_CR84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monnette","year":"2021","unstructured":"Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, et al. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16(1):36. https:\/\/doi.org\/10.1186\/s13023-020-01667-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1095_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, et al. Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS ONE. 2018;13(6): e0199657. https:\/\/doi.org\/10.1371\/journal.pone.0199657.","journal-title":"PLoS ONE"},{"issue":"14","key":"1095_CR86","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","volume":"95","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, Bartels B, Asselman FL, van Eijk RPA, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95(14):e1988\u201398. https:\/\/doi.org\/10.1212\/WNL.0000000000010540.","journal-title":"Neurology"},{"issue":"3","key":"1095_CR87","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.23937","volume":"49","author":"SJ Cano","year":"2014","unstructured":"Cano SJ, Mayhew A, Glanzman AM, Krosschell KJ, Swoboda KJ, Main M, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve. 2014;49(3):422\u201330. https:\/\/doi.org\/10.1002\/mus.23937.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1095_CR88","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.nmd.2014.01.003","volume":"24","author":"E Mazzone","year":"2014","unstructured":"Mazzone E, De Sanctis R, Fanelli L, Bianco F, Main M, van den Hauwe M, et al. Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. Neuromuscul Disord. 2014;24(4):347\u201352. https:\/\/doi.org\/10.1016\/j.nmd.2014.01.003.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"1095_CR89","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","volume":"27","author":"F Rouault","year":"2017","unstructured":"Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, et al. Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients. Neuromuscul Disord. 2017;27(5):428\u201338. https:\/\/doi.org\/10.1016\/j.nmd.2017.01.018.","journal-title":"Neuromuscul Disord"},{"key":"1095_CR90","doi-asserted-by":"publisher","first-page":"S843","DOI":"10.1016\/j.jval.2019.09.2347","volume":"22","author":"F Woodcock","year":"2019","unstructured":"Woodcock F, Mumby-Croft J, Ghosh S, Chandler F, Godfrey J, Crossley E. PRO16 project Hercules: a case study in developing a multi-company, flexible cost-effectiveness model in a rare disease. Value Health. 2019;22:S843. https:\/\/doi.org\/10.1016\/j.jval.2019.09.2347.","journal-title":"Value Health."},{"issue":"Suppl 1","key":"1095_CR91","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1185\/030079904X1980","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5-26. https:\/\/doi.org\/10.1185\/030079904X1980.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1095_CR92","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JND-200534","volume":"7","author":"VA Sansone","year":"2020","unstructured":"Sansone VA, Walter MC, Attarian S, Delstanche S, Mercuri E, Lochmuller H, et al. Measuring outcomes in adults with spinal muscular atrophy\u2014challenges and future directions\u2014meeting report. J Neuromuscul Dis. 2020;7(4):523\u201334. https:\/\/doi.org\/10.3233\/JND-200534.","journal-title":"J Neuromuscul Dis."},{"key":"1095_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00413-4","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy\u2014insights and challenges in the treatment era. Nat Rev Neurol. 2020. https:\/\/doi.org\/10.1038\/s41582-020-00413-4.","journal-title":"Nat Rev Neurol"},{"key":"1095_CR94","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1016\/j.jval.2020.04.1284","volume":"23","author":"N Paracha","year":"2020","unstructured":"Paracha N, Gorni K, Hudson P. PRO62 spinal muscular atrophy: development of natural history models for disease subtypes. Value Health. 2020;23:S339. https:\/\/doi.org\/10.1016\/j.jval.2020.04.1284.","journal-title":"Value Health."},{"key":"1095_CR95","doi-asserted-by":"crossref","unstructured":"Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. OUP Catalogue. 2016.","DOI":"10.1093\/med\/9780198725923.001.0001"},{"key":"1095_CR96","doi-asserted-by":"publisher","unstructured":"Pierzchlewicz K, Kepa I, Podogrodzki J, Kotulska K. Spinal muscular atrophy: the use of functional motor scales in the era of disease-modifying treatment. Child Neurol Open. 2021;8:2329048X211008725. https:\/\/doi.org\/10.1177\/2329048X211008725.","DOI":"10.1177\/2329048X211008725"},{"issue":"1","key":"1095_CR97","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17(1):68. https:\/\/doi.org\/10.1186\/s12883-017-0853-y.","journal-title":"BMC Neurol"},{"key":"1095_CR98","unstructured":"Cruz R, Lenz M, Belter L, Hobby K, Jarecki J, Smart T. The voice of the patient report for spinal muscular atrophy. 2018. https:\/\/www.curesma.org\/wp-content\/uploads\/2018\/01\/SMA-VoP-for-publication-1-22-2018.pdf. Accessed 6 Nov 2019."},{"key":"1095_CR99","unstructured":"Food and Drug Administration. Methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. White Oak; 2018. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/patient-focused-drug-development-guidance-methods-identify-what-important-patients-and-select. Accessed 6 Nov 2019."},{"issue":"1","key":"1095_CR100","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","volume":"11","author":"C Klug","year":"2016","unstructured":"Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11(1):58. https:\/\/doi.org\/10.1186\/s13023-016-0424-0.","journal-title":"Orphanet J Rare Dis"},{"key":"1095_CR101","unstructured":"Shieh P, Gu T, Chen E, Punekar R, Tan H. Treatment patterns and cost of care among patients with spinal muscular atrophy. In: Cure SMA. 2017."},{"issue":"7","key":"1095_CR102","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-014-0153-y","volume":"32","author":"KA Khan","year":"2014","unstructured":"Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE. Mapping EQ-5D utility scores from the PedsQL generic core scales. Pharmacoeconomics. 2014;32(7):693\u2013706. https:\/\/doi.org\/10.1007\/s40273-014-0153-y.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1095_CR103","doi-asserted-by":"publisher","first-page":"A559","DOI":"10.1016\/j.jval.2017.08.911","volume":"20","author":"A Lloyd","year":"2017","unstructured":"Lloyd A, Gallop K, Thompson R, Vaidya S, Teynor M. Estimation of the health-related quality of life benefits of treatment for spinal muscular atropy (SMA). Value Health. 2017;20(9):A559. https:\/\/doi.org\/10.1016\/j.jval.2017.08.911.","journal-title":"Value Health."}],"updated-by":[{"DOI":"10.1007\/s40273-022-01138-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000}}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01095-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T11:19:43Z","timestamp":1649503183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01095-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":103,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01095-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"20 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40273-022-01138-6","URL":"https:\/\/doi.org\/10.1007\/s40273-022-01138-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This article is published in a special edition journal supplement wholly funded by F. Hoffmann-La Roche Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"During the preparation of this manuscript, C. Simone Sutherland was employed by F. Hoffmann-La Roche and owns stocks in Roche. During the preparation of this manuscript, Noman Paracha was employed by F. Hoffmann-La Roche and owns stocks in Roche. Pollyanna Hudson\u2019s and Stephen Mitchell\u2019s employer, Mtech Access, was commissioned by Roche, and therefore received a consulting fee to conduct the systematic review presented in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NP and CSS conceptualised the study and all authors contributed to the study design. PH and SM conducted the literature search, data extraction, initial summary of results and quality assessment. All authors contributed to data interpretation and development of the manuscript, including figures, tables and online resource materials. All authors approved the final version of the manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}